Definium Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Operating income | -$166.3 | -$103.9 | -$93.9 | -$66.3 | -$93.9 |
| Net income | -$183.8 | -$108.7 | -$95.7 | -$56.8 | -$93.0 |
| Balance Sheet | |||||
| Total debt | $41.0 | $22.0 | $15.0 | — | — |
Shares outstanding 134.4M · Free float 98.1%
Annual filing data through FY ended December 31, 2025; float as of October 5, 2026.